Ucb S.a. · EURONEXT:UCB
Ucb — ESG Presentation (November 2023)
51 slides from Ucb's sustainability presentation, November 2023
Slide 1: UCB ESG Roadshow
UCB ESG Roadshow November 2023
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor Forward-looking statements This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions.
Slide 3: Agenda
01 Sustainability is an integrated part of UCB Proprietary and Confidential Property of UCB Agenda 02 Creating value for our key stakeholders in society 03 Summary of our performance 3
Slide 4: Sustainability is an integrated part of UCB
01 Sustainability is an integrated part of UCB Proprietary and Confidential Property of UCB 4
Slide 5: UCB key figures
UCB key figures* Our areas of focus Proprietary and Confidential Property of UCB >3.4 million 36 8 700 patients treated presence in employees countries neurology 5.5 billion € 30% 22.8% immunology revenue R&D/revenue ratio adj. EBITDA/ revenue ratio *As of December 2022 More details in the 2022 UCB
Slide 6: We are defined by our purpose
We are defined by our purpose: Creating value for patients now and into the future. Proprietary and Confidential Property of UCB And sustainability is at our core, guided by our 2021 materiality assessment. 6
Slide 7: Adapting UCB performance reporting to EU CSRD requirements
Adapting UCB performance reporting to EU CSRD* requirements while continuing to report in accordance with SASB** Our 2023 updated materiality assessment is guiding which CSRD standards are applicable to UCB Proprietary and Confidential Property of UCB *EU CSRD: European Corporate Sustainability Repo
Slide 8: Sustainability is at the core of UCB
Sustainability is at the core of UCB Our focus on long term value creation is supported Sustainable value creation in Art. 3.1.1 of by Financiere de Tubize, our reference shareholder the UCB Corporate Governance Charter 2% Proprietary and Confidential Property of UCB 7% Shareholder structure* Financ
Slide 9: UCB Board of Directors
UCB Board of Directors • 13 members o Mandate: 4 year o Age limit: 70 • 5 women (38%) • 7 independent directors (54%) Proprietary and Confidential Property of UCB • 7 countries • One executive board member (CEO) • Convincing mix of skills & experience including on sustainability and ESG matters Comp
Slide 10: UCB Board Committees
UCB Board Committees Proprietary and Confidential Property of UCB Composition and biographies available on: https://www.ucb.com/investors/UCB-Governance 10
Slide 11: Our governance supports our commitment to sustainable performance
Our governance supports our commitment to sustainable performance Oversees sustainability as a whole and through BOARD OF its committees DIRECTORS Proprietary and Confidential Property of UCB CEO & EXTERNAL Adviser to CEO and leadership. Provides an annual report to the Board. Own sustainable perfor
Slide 12: UCB External Sustainability Advisory Board
UCB External Sustainability Advisory Board Charlotte ERSBØLL Teresa FOGELBERG Bright SIMONS Founding partner at Hansen & Ersbøll Agenda Founder and President of mPedigree Proprietary and Confidential Property of UCB Background Chair of the UCB ESAB Background Co-founder and Deputy Chief Executive of
Slide 13: Our ethics in action
Our ethics in action 100% of UCB employees completed the Code of Conduct training in 2022 Proprietary and Confidential Property of UCB Yearly ethical culture survey has shown in 2021 that: • 91.7% of respondents agree they have a personal responsibility for making sure UCB behaves ethically • 91.3%
Slide 14: Driving Sustained Growth While Making a Positive Impact on Society
Driving Sustained Growth While Making a Positive Impact on Society (as of Dec 2022*) Value for patients >3.4 million patients treated 35% reimbursement for all patients within regulatory labels 42% reimbursement for some patients but not all within regulatory labels 9 medicines in clinical developme
Slide 15: We Are Recognized for Our ESG Performance Across Key Rating Providers
We Are Recognized for Our ESG Performance Across Key Rating Providers ESG Rating Providers Index Memberships 2021 2022 2023 Industry rank 3 / 397 of the 16.8 16.8 17.0 Proprietary and Confidential Property of UCB biotechnology subindustry Selected to be part of the new BEL ESG Index, with UCB is a l
Slide 16: Linking remuneration to sustainable performance
Linking remuneration to sustainable performance We aim to drive sustainable value creation while fostering a working environment where people can thrive. Proprietary and Confidential Property of UCB Our reward principles serve as a basis Stimulating sustained high performance for what UCB aims to in
Slide 17: Key performance indicators influence executive remuneration
Collective financial and extra-financial key performance indicators influence executive remuneration BONUS LTI – PERFORMANCE SHARES Proprietary and Confidential Property of UCB Individual Corporate Negative • 75%: performance performance modifier • Incentivize the achievement of 3-year revenue and c
Slide 18: Creating value for our key stakeholders in society
02 Creating value for our key stakeholders in society Proprietary and Confidential Property of UCB 18
Slide 19: Creating Value for Patients
Creating Value for Patients Proprietary and Confidential Property of UCB We innovate to bring differentiated solutions with unique outcomes that help diverse patients achieve their life goals. We are committed to improving access to these solutions for all patients who need them in a way which is vi
Slide 20: Remarkable UCB Clinical Development Pipeline
Remarkable UCB Clinical Development Pipeline Nine clinical development assets, 11 ongoing studies PHASE 1 PHASE 2 PHASE 3 rozanolixizumab (FcRn inhibitor) Targeted FcRn inhibition in a population that has a severe brain MOG-antibody disease inflammation and has no approved treatment options Autoimmu
Slide 21: Increasing diversity in clinical trials
Working to ensure that participants in UCB clinical trials are reflective of the populations that will ultimately benefit from our new medicines Increasing diversity in clinical trials Race and ethnicity distribution among UCB US trial participants* Key Programs compared with US 2020 CENSUS BUREAU**
Slide 22: We put access to our solutions high on our agenda
We put access to our solutions high on our agenda OUR APPROACH • Integrating access from early development • Engaging with external stakeholders Our goal is that by 2030, all patients who Proprietary and Confidential Property of UCB • Conducting health equity research projects need our medicines in
Slide 23: Working in partnership with healthcare systems to ensure timely access
Working in partnership with healthcare systems to ensure timely access to patients who need our solutions in countries where we operate Access Performance Index 2022* How we calculate UCB Access Performance Index • In a specific country, access is evaluated at decision Proprietary and Confidential P
Slide 24: Patient assistance programs and health equity research projects
Patient assistance programs and health equity research projects to address the needs of under-served populations in the US Patients benefitting from UCB Understanding and addressing health disparities to improve patient assistance programs* experience and health outcomes 120,000 “Hispanic CARE” Rese
Slide 25: Our 1st social business in Mumbai, India
Our 1st social business in Mumbai, India for persons with epilepsy Goal is to improve the situation of persons Number of patients enrolled in UCB 1st social business as of with epilepsy on a sustainable basis* September 2023 (per month) 3000 Proprietary and Confidential Property of UCB 2500 2402 220
Slide 26: Creating value for our employees
Creating value for our employees Proprietary and Confidential Property of UCB At UCB, we value and nurture diverse perspectives and backgrounds and show respect and care for each other. We are made stronger because of our culture of innovation and collaboration which allows us to create value for pa
Slide 27: UCB employees see purpose in their work
UCB employees see purpose in their work Proprietary and Confidential Property of UCB Global Engagement Score is the average of responses to: 76% Purpose The work that I do at UCB is meaningful to me. 74/100 Retention I rarely think about looking for a job at a different company. Global Pride I feel
Slide 28: We continue to prioritize health, safety and wellbeing of our people
We continue to prioritize the health, safety and wellbeing of our people 2019 Launch Safety beyond 0 program (securing potential Life Changing Activities) 2020 • Delivery Model definition Proprietary and Confidential Property of UCB • First Health, Safety and Wellbeing Survey 2021 • > 95% of our emp
Slide 29: We measure our progress on health, safety and wellbeing
And we measure our progress on health, safety and wellbeing Health, Safety and Wellbeing Index 2022* Loss time Incident 100% SAFETY Rate (performance vs target) Proprietary and Confidential Property of UCB Annual Global Survey on current HSWB status 80,4% and areas for improvement 72% Employee metri
Slide 30: We are on track to deliver on our DE&I aspirations
We are on track to deliver on our DE&I aspirations 2025 Aspirations Our progress towards 2025 8 Employee Resource Groups (ERGs) in 2022* Gender diversity 2022: 38%/62% Gender balance at executive level: 45/55 by 2025 Proprietary and Confidential Property of UCB MEMBERSHIP WORKFORCE Under-represented
Slide 31: Valuing the Planet
Valuing the Planet Proprietary and Confidential Property of UCB We take a long-term view of our business activities. We strive to uncouple our growth from our environmental footprint so that we can protect the planet for future generations. 31
Slide 32: Protecting human health also means safeguarding the health of our planet
It is now clearer than ever that protecting human health also means safeguarding the health of our planet Proprietary and Confidential Property of UCB Source: World Health Organization. Link. 32
Slide 33: Clear targets for becoming carbon neutral by 2030
We set clear targets* for becoming carbon neutral by 2030 and reducing our environmental impact Proprietary and Confidential Property of UCB Reduce CO2e emissions and become Reduce water withdrawal by 20% by Reduce waste production by 25% by carbon neutral for the operations we 2030. 2030. control d
Slide 34: Our path to carbon neutrality by 2030
Our path to carbon neutrality by 2030 Scope 3 “goods and service Key initiatives across scope 1,2 and 3 suppliers”: % of suppliers (By CO2e emissions) committed to • Move to energy generated from renewable Sciences Based Targets alike* sources, purchased or produced on UCB sites 35% (solar farm in B
Slide 35: Reducing water withdrawal by 20% by 2030
Reducing water withdrawal by 20% by 2030 compared to our 2015 baseline Water (m3)* Key programs 1,200,000 Proprietary and Confidential Property of UCB Reducing 1,000,000 335,539 • Replace existing equipment, processes and behaviors with more ecofriendly equivalents Forecasting “Do Nothing” 800,000 •
Slide 36: Green-by-design approach to minimize waste generation
We follow a green-by-design approach to minimize waste generation Key programs Total waste (Tons) 12,000 Proprietary and Confidential Property of UCB 10,000 • Reducing fresh raw materials use in new 9,745 chemical synthesis 8,712 8,000 • Zero domestic plastic in all our sites 7,090 6,970 6,605 6,752
Slide 37: Creating value for our communities
Creating value for our communities Proprietary and Confidential Property of UCB We aim to support people living in the communities where we operate, deepening our local connections and helping to address disparities in health and education amongst under-served populations 37
Slide 38: Committed to create value for communities where we live and work
We are committed to create value for communities where we live and work Supporting underserved populations through philanthropy Proprietary and Confidential Property of UCB Supported 15 organizations in the US that provided STEM* UCB Community Health Fund education opportunities to more 143 projects
Slide 39: Supporting STEM education for more than 14,000 students
Supporting STEM education for more than 14,000 students in 2022 with a focus on K-12 youngsters in underserved populations Proprietary and Confidential Property of UCB 39
Slide 40: UCB Community Health Fund
UCB Community Health Fund Supporting underserved populations in communities where UCB operates € 6.5 million 143 distributed in… projects worldwide Proprietary and Confidential Property of UCB Belgium UK & Ireland 2.661.000 € Canada 552.000 € 68 projects 20.000 € 14 projects 1 project East Europe 37
Slide 41: Creating value for our shareholders
Creating value for our shareholders Proprietary and Confidential Property of UCB We pay attention to patient insights and societal challenges to guide how we do business, create value and generate sustainable business growth. We aim to deliver long-term value to our shareholders, now and into the fu
Slide 42: Strong Balance Sheet
Strong Balance Sheet • Net debt increase reflects Zogenix acquisition in 2022; Net debt/EBITDA 1.6x • Good cash flow generation excluding Zogenix impact, strong cash position • Board of Directors proposes a dividend of €1.33 per share (gross), +2% - in-line with UCB’s dividend policy and underlying
Slide 43: 2023 HY Financial Highlights
2023 HY Financial Highlights Inflection point towards growth and investment behind multiple launches HY 2023 Actual CER Net Sales € 2 378 M (-12%; -14% CER) Revenue Good portfolio growth compensated by LOE impacts VIMPAT ® and E KEPPRA® € 2 589 M -11% -13% underlying net sales growth - adjusted for
Slide 44: Financial Guidance for 2023 – Confirmed
Financial Guidance for 2023 – Confirmed Ready for growth, investing behind multiple launches, Zogenix acquisition becoming earnings accretive Revenue expected € 5.15 - 5.35 bn Peak sales guidance • Robust product portfolio • FINTEPLA ® • Expected launches bimekizumab, Proprietary and Confidential Pr
Slide 45: Guidance 2025
Guidance 2025 At least € 6bn top line Financial guidance Low- to mid-thirties adj. EBITDA margin Improved ESG rating performance Proprietary and Confidential Property of UCB 2025 How We Get There… Topline Evolution Building Blocks Margin BRIVIACT ® 2025 NAYZILAM® Adjusted EVENITY® Gross Improving th
Slide 46: Inflection point reached
INFLECTION POINT CREATING Reached Value for all stakeholders, now and into the future BRINGING Proprietary and Confidential Property of UCB • New treatment options for people living with severe diseases • Growth and healthy profitability on a sustainable basis DELIVERING • Approvals and submissions
Slide 47: Summary of our performance
03 performance Summary of our 47 Proprietary and Confidential Property of UCB
Slide 48: 2022 UCB performance as reported in our integrated annual report
2022 UCB performance as reported in our integrated annual report Proprietary and Confidential Property of UCB 9 late-stage assets in Preserved jobs while € 5.52 bn revenues >140 global academic -58% CO 2 emissions we pipeline mitigating headwinds € 1.26 bn adjusted partnerships directly control vs.
Slide 49: Thank you… Question time!
Proprietary and Confidential Property of UCB Thank you… Question time ! Proprietary and Confidential Property of UCB 49
Slide 50: The Roadshow Team
The Roadshow Team Veronique Toully (veronique.toully@ucb.com) Check out our IR App & • Head of Sustainability Proprietary and Confidential Property of UCB • Phone: +32 2 559 9229 stay tuned to UCB wherever you go! Xavier Michel (xavier.michel@ucb.com) • Head of Corporate Secretary Department • Phone
Slide 51: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB